PROCEPT BioRobotics (PRCT) , a surgical robotics company, recently achieved a significant milestone as it received FDA 510(k) clearance for its HYDROS Robotic System. This next-generation platform is set to revolutionize urological care by offering advanced features designed to enhance efficiency, precision and clinical outcomes. This latest regulatory clearance is expected to help PROCEPT expand in the specialized field of Aquablation therapy within transformative urological solutions. The therapy is, of l ...

SAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced FDA 510(k) clearance of its next-generation platform, the HYDROS™ Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is d ...

PROCEPT BioRobotics Today | --- | --- | |----------------------|-------| | | | | | | | | | | PRCT | | | PROCEPT BioRobotics | | | $64.60 | | | +1.27 (+2.01%) | | | 52-Week Range $24.83 | | | ▼ | | | $77.00 | | | Price Target $66.00 | | | Add to Watchlist | | Surgical robotics company PROCEPT BioRobotics Co. NASDAQ: PRCT developed the AquaBeam Robotic System for the treatment of benign prostatic hyperplasia (BPH) among aging men. The company went public during the special purpose acquisition company (SPAC) m ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q2 2024 Earnings Conference Call August 1, 2024 4:30 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - President & Chief Executive Officer Sham Shiblaq - Executive VP, Chief Commercial Officer Kevin Waters - Executive VP, Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Matthew O'Brien - Piper Sandler Richard Newitter - Truist Brandon Vasquez - William Blair Joshua Jennings - TD Cowen Dino W ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT BioRobotics Corporation (Exact name of registrant as specified in its charter) Delaware 26-0199180 (State or other ...

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.85%. A quarter ago, it was expected that this company would post a loss of $0.55 per share when it actually produced a loss of $0.51, delivering a surprise of 7.27%. Over the last four quarters, the comp ...

PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance SAN JOSE, Calif., August 1, 2024 -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights • Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% com ...

SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% compared to the prior period in 2023 U.S. handpiece and consumables revenue of $27.3 million for the se ...

SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% compared to the prior period in 2023 U.S. handpiece and consumables revenue of $27.3 million for the se ...

Investors interested in listening to the conference call may do so by following one of the below links: Dial-in registration for sell-side research analysts: https://register.vevent.com/register/BI7bf6aa315a2b44d6a070a16b6608b822 An archived recording will be available on the "Investors" section of the Company's website at: https://ir.procept-biorobotics.com. Each webcast will be available for replay for at least 90 days after the event. PROCEPT BioRobotics is a surgical robotics company focused on advancin ...